Announced details
New or existing projects related to the manufacture of antibacterial drug products, vaccines and dialysis-related products, and the wider adoption of related treatments
Third-party assessment organization that provided a second-party opinion on this framework
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
The International Capital Market Association (ICMA) Social Bond Principles 2025, the Social Loan Principles 2025 issued by the Loan Market Association (LMA) and others, and a third-party assessment by R&I
| Item | Details |
|---|---|
| Names of Products / Services Covered | Antibacterial drug products, Vaccines, Dialysis-related products, Social Finance Framework |
| Counterparty | R&I |
| Relationship with the Company | Third-party assessment organization that provided a second-party opinion on this framework |
| Applicable area | New or existing projects related to the manufacture of antibacterial drug products, vaccines and dialysis-related products, and the wider adoption of related treatments |
| Source | The International Capital Market Association (ICMA) Social Bond Principles 2025, the Social Loan Principles 2025 issued by the Loan Market Association (LMA) and others, and a third-party assessment by R&I |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To continuously raise the funds required for business activities through social finance, and to establish policies for organizing the use of proceeds and clarifying the eligible period for refinancing proceeds.